Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

StopBleeding The first effective and safe reversal agent to stop or prevent life-threatening bleeding in patients taking the emerging generation of anticoagulants.

Coordinator
Varmx BV, Netherlands
Runs
1 September 2022 to 31 March 2025
Status
Running
EU funding
€2.5m
Total cost
€4.8m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190169569

What the project is doing

In the project's own words, from its summary on CORDIS.

50 Million patients worldwide use oral anticoagulants to prevent venous thrombosis and stroke. Since the last decade, unpredictable and risky indirect anticoagulant treatments are being replaced by the latest generation of blood-thinning medication: Factor Xa Direct Oral Anticoagulants (FXa-DOACs, used by >10 million patients in EU+US). With superior predictability, efficacy and safety profiles, these life-saving medications remain associated with a risk of uncontrolled and severe bleeding.

Alarmingly, there is no safe reversal agent that restores blood clotting in patients who take FXa-DOACs, resulting in life-threatening bleeding episodes and >400k hospital admissions. To address the urgent unmet need, VarmX has developed VMX-C001, the first effective and safe reversal agent to FXa-DOACs. VarmX requests a €2,5M in grant and €15M in equity EIC to accelerate upscaling and improve the cost-effectiveness of the complex manufacturing process required to produce VMX-C001.

Topics

Who is involved

OrganisationCityCountryRole
Varmx BVLeidenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI